Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure

From University of Washington–Harborview Prehospital Emergency Care Research and Training Center and Harborview Medical Center, Seattle, Washington; Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada; University of Alberta, Edmonton, Alberta, Canada; and Case Western Reserve University, Cleveland, Ohio.

View larger version:
- In this window
- In a new window
Figure 1. Markov model of medical therapy for heart failure.
View larger version:
- In this window
- In a new window
Figure 2. Markov model of cardiac resynchronization therapy (CRT) for heart failure.
View larger version:
- In this window
- In a new window
Figure 3. For the base-case point estimate ( ), incremental costs = $30 252 and incremental effect = 0.282 quality-adjusted life-year ( ). Distribution of incremental costs versus incremental effects for cardiac resynchronization therapy versus medical therapy.white XQALY
View larger version:
- In this window
- In a new window
Appendix Figure. QALY = quality-adjusted life-year. Cost-effectiveness acceptability curve.